The submission represents Dimericon Therapeutics, a legitimate Swiss biotech company targeting protein-protein interactions for oncology. However, the submission content is of extremely low quality, containing factually incorrect claims (e.g., 'most people have used my product' for a pre-clinical firm) and nonsensical metrics ('marketcap: 500000'). While the underlying technology (Dimericons/helix dimers) is innovative and verified externally, the submission fails to accurately demonstrate this value, resulting in a low score driven by poor data quality and lack of verifiable traction evidence in the input.
Ready to Compete for $150k+ in Prizes?
Move this data into a HackerNoon blog draft to become eligible for your share of $150k+ in cash and software prizes
Score Breakdown
Project Details
Algorithm Insights
Recommendations to Increase Usefulness Score
Document User Growth
Provide specific metrics on user acquisition and retention rates
Showcase Revenue Model
Detail sustainable monetization strategy and current revenue streams
Expand Evidence Base
Include testimonials, case studies, and third-party validation
Technical Roadmap
Share development milestones and feature completion timeline